KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Net Income: 2010-2025

Historic Net Income for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -$35.0 million.

  • Nektar Therapeutics' Net Income rose 5.58% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.4 million, marking a year-over-year increase of 32.63%. This contributed to the annual value of -$119.0 million for FY2024, which is 56.90% up from last year.
  • Per Nektar Therapeutics' latest filing, its Net Income stood at -$35.0 million for Q3 2025, which was up 10.76% from -$39.2 million recorded in Q2 2025.
  • Over the past 5 years, Nektar Therapeutics' Net Income peaked at $7.2 million during Q4 2024, and registered a low of -$159.1 million during Q2 2022.
  • Its 3-year average for Net Income is -$46.9 million, with a median of -$42.1 million in 2023.
  • In the last 5 years, Nektar Therapeutics' Net Income plummeted by 56.90% in 2021 and then skyrocketed by 117.19% in 2024.
  • Nektar Therapeutics' Net Income (Quarterly) stood at -$146.9 million in 2021, then skyrocketed by 54.66% to -$66.6 million in 2022, then soared by 36.82% to -$42.1 million in 2023, then soared by 117.19% to $7.2 million in 2024, then climbed by 5.58% to -$35.0 million in 2025.
  • Its Net Income was -$35.0 million in Q3 2025, compared to -$39.2 million in Q2 2025 and -$46.4 million in Q1 2025.